TWI366603B - Chimeric adenoviruses for use in cancer treatment - Google Patents

Chimeric adenoviruses for use in cancer treatment

Info

Publication number
TWI366603B
TWI366603B TW094117065A TW94117065A TWI366603B TW I366603 B TWI366603 B TW I366603B TW 094117065 A TW094117065 A TW 094117065A TW 94117065 A TW94117065 A TW 94117065A TW I366603 B TWI366603 B TW I366603B
Authority
TW
Taiwan
Prior art keywords
cancer treatment
chimeric adenoviruses
adenoviruses
chimeric
cancer
Prior art date
Application number
TW094117065A
Other languages
English (en)
Other versions
TW200611974A (en
Inventor
Paul Harden
Terry Hermiston
Irene Kuhn
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of TW200611974A publication Critical patent/TW200611974A/zh
Application granted granted Critical
Publication of TWI366603B publication Critical patent/TWI366603B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
TW094117065A 2004-05-26 2005-05-25 Chimeric adenoviruses for use in cancer treatment TWI366603B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57485104P 2004-05-26 2004-05-26

Publications (2)

Publication Number Publication Date
TW200611974A TW200611974A (en) 2006-04-16
TWI366603B true TWI366603B (en) 2012-06-21

Family

ID=35355425

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094117065A TWI366603B (en) 2004-05-26 2005-05-25 Chimeric adenoviruses for use in cancer treatment

Country Status (33)

Country Link
US (6) US7510868B2 (zh)
EP (1) EP1749098B1 (zh)
JP (1) JP4787936B2 (zh)
KR (1) KR101169109B1 (zh)
CN (3) CN104263703B9 (zh)
AR (2) AR049188A1 (zh)
AT (1) ATE491799T1 (zh)
AU (1) AU2005250396B2 (zh)
BR (2) BRPI0510475B8 (zh)
CA (2) CA2567094C (zh)
CR (1) CR8794A (zh)
DE (1) DE602005025340D1 (zh)
DK (1) DK1749098T3 (zh)
EC (1) ECSP067088A (zh)
ES (1) ES2358204T3 (zh)
GT (1) GT200500129A (zh)
HK (3) HK1109421A1 (zh)
HR (1) HRP20110179T1 (zh)
IL (2) IL179098A (zh)
MX (1) MXPA06013570A (zh)
MY (1) MY140829A (zh)
NO (1) NO340708B1 (zh)
NZ (1) NZ551443A (zh)
PA (1) PA8634201A1 (zh)
PE (1) PE20060277A1 (zh)
PL (1) PL1749098T3 (zh)
PT (1) PT1749098E (zh)
RU (1) RU2448157C2 (zh)
TW (1) TWI366603B (zh)
UA (1) UA89957C2 (zh)
UY (1) UY28926A1 (zh)
WO (1) WO2005118825A2 (zh)
ZA (1) ZA200610763B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
US9217026B2 (en) * 2006-11-13 2015-12-22 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
WO2008080003A2 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
KR100856310B1 (ko) 2007-02-28 2008-09-03 삼성전기주식회사 이동통신 단말기
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
AP2014007993A0 (en) * 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
BR112015021297A2 (pt) * 2013-02-28 2017-10-10 Psioxus Therapeutics Ltd um processo para a produção de adenovírus.
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
RU2671558C2 (ru) * 2013-06-14 2018-11-02 Псайоксус Терапьютикс Лимитед Режим введения и составы для аденовирусов типа в
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
PT3021859T (pt) 2013-10-25 2018-03-09 Psioxus Therapeutics Ltd Adenovírus oncolíticos munidos de genes heterólogos
GB2531821A (en) * 2013-10-25 2016-05-04 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
JP2017529070A (ja) 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
EP3391892A1 (en) * 2015-04-30 2018-10-24 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
WO2018018073A1 (en) * 2016-07-25 2018-02-01 Ascend Biopharmaceuticals Ltd Methods of treating cancer
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3503918B1 (en) 2016-08-29 2020-09-30 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN111246867B (zh) 2017-06-01 2024-04-12 阿卡米斯生物公司 溶瘤病毒和方法
CA3074678A1 (en) 2017-09-05 2019-03-14 GLAdiator Biosciences, Inc. Method of targeting exosomes
US11746334B2 (en) 2018-11-21 2023-09-05 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
CA3138527C (en) 2019-04-29 2024-03-12 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) * 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
ATE519854T1 (de) * 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
EP1083228A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP2003534806A (ja) * 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
US7459153B2 (en) * 2001-01-04 2008-12-02 Wadell Goeran Viral vectors for gene therapy
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof

Also Published As

Publication number Publication date
US20120231524A1 (en) 2012-09-13
EP1749098B1 (en) 2010-12-15
AR090647A2 (es) 2014-11-26
ECSP067088A (es) 2007-01-26
US9234185B2 (en) 2016-01-12
US7510868B2 (en) 2009-03-31
HRP20110179T1 (hr) 2011-04-30
JP4787936B2 (ja) 2011-10-05
RU2006145071A (ru) 2008-07-10
CA2567094C (en) 2014-11-25
AU2005250396B2 (en) 2010-11-11
DK1749098T3 (da) 2011-04-04
UY28926A1 (es) 2006-01-31
JP2008500051A (ja) 2008-01-10
CN1997746A (zh) 2007-07-11
BRPI0510475B1 (pt) 2020-09-29
US20130230902A2 (en) 2013-09-05
ATE491799T1 (de) 2011-01-15
US9034344B2 (en) 2015-05-19
EP1749098A2 (en) 2007-02-07
BRPI0510475A (pt) 2007-11-06
CN1997746B (zh) 2012-09-26
DE602005025340D1 (de) 2011-01-27
CA2836987A1 (en) 2005-12-15
US20130209409A1 (en) 2013-08-15
AR049188A1 (es) 2006-07-05
CN102816742A (zh) 2012-12-12
CN102816742B (zh) 2014-04-09
BR122013008865B1 (pt) 2020-11-24
ZA200610763B (en) 2009-06-24
US20130217095A1 (en) 2013-08-22
UA89957C2 (ru) 2010-03-25
NO20066002L (no) 2006-12-22
WO2005118825A3 (en) 2006-11-23
CA2567094A1 (en) 2005-12-15
IL179098A (en) 2015-09-24
BR122013008865B8 (pt) 2021-05-25
WO2005118825A2 (en) 2005-12-15
ES2358204T3 (es) 2011-05-06
BRPI0510475B8 (pt) 2021-05-25
TW200611974A (en) 2006-04-16
US20090227000A1 (en) 2009-09-10
NZ551443A (en) 2010-01-29
CR8794A (es) 2007-08-28
US20150037874A1 (en) 2015-02-05
CA2836987C (en) 2016-07-05
US8765463B2 (en) 2014-07-01
PA8634201A1 (es) 2006-11-09
MXPA06013570A (es) 2007-02-08
RU2448157C2 (ru) 2012-04-20
IL179098A0 (en) 2007-03-08
CN104263703B9 (zh) 2019-12-17
IL226820A0 (en) 2013-07-31
KR20070020302A (ko) 2007-02-20
HK1179655A1 (zh) 2013-10-04
GT200500129A (es) 2006-03-23
CN104263703B (zh) 2018-01-09
PT1749098E (pt) 2011-02-02
KR101169109B1 (ko) 2012-07-26
HK1205529A1 (zh) 2015-12-18
CN104263703A (zh) 2015-01-07
IL226820A (en) 2017-07-31
US9115337B2 (en) 2015-08-25
PE20060277A1 (es) 2006-05-25
AU2005250396A1 (en) 2005-12-15
HK1109421A1 (en) 2008-06-06
US20050265973A1 (en) 2005-12-01
PL1749098T3 (pl) 2011-05-31
US8158599B2 (en) 2012-04-17
NO340708B1 (no) 2017-06-06
MY140829A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
HK1205529A1 (zh) 用於治療癌症的嵌合腺病毒
HK1201182A1 (zh) 用於治療癌症或腫瘤的聚乙二醇化的
HK1136822A1 (en) Therapeutic compounds and their use in cancer
EP1814544A4 (en) CANCER TREATMENTS
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
EP1747284A4 (en) DIAGNOSTICS AND THERAPEUTICS OF CANCER
PT1830847E (pt) Tratamento para o cancro
EP2023950A4 (en) CANCER TREATMENT WITH URODILATIN
IL185258A (en) Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human
GB0400700D0 (en) Compounds useful in therapy
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
GB0428187D0 (en) Cancer treatment
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
GB0413346D0 (en) Treating cancer
GB0507685D0 (en) Cancer treatment
GB0404675D0 (en) Cancer treatment
PL378586A1 (pl) Zastosowanie analogów kalcypotriolu w leczeniu chorób nowotworowych
GB0516610D0 (en) Compounds for use in therapy
GB0522671D0 (en) Spisulosine compounds for use in cancer therapy
GB0803201D0 (en) Two-part dressing suitable for use in surgery
GB0423117D0 (en) Compounds for use in therapy
GB0604794D0 (en) Spisulosine compounds for use in cancer therapy